430 / 1851
Key Points
Molecularly targeted agents are less toxic than cytotoxic
agents (antibodies/small molecular
resistances
Molecularly targeted agents work by targeting the genetic
changes(s) in cancer cells
Chromosomal translocation
Gene duplication
Gene mutation
Risk for secondary mutations high
Risk for paraxodical activation of pro-tumorigenic
wildtype-signal transduction cascade exists (Raf-
inhibitors)
To improve cancer treatment, we need to better
understand the
differences between cancer and normal
cells